Perspective Therapeutics (CATX) vs InfuSystems (INFU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InfuSystems (INFU) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 36.6% versus a loss of 29.1%. Over five years, INFU leads with a +4.2% price change compared with -60.3% for CATX. Perspective Therapeutics is the larger company by market cap ($309.4 million vs $267.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | INFU |
|---|---|---|
| Share price | $2.71 | $13.41 |
| Market cap | $309.35M | $267.09M |
| 1-day change | +10.16% | +0.60% |
| YTD return | -10.55% | +49.50% |
| 1-year return | -29.11% | +36.56% |
| 5-year return | -60.32% | +4.20% |
| P/E ratio (TTM) | — | 33.52 |
| Forward P/E | — | 25.79 |
| EPS (TTM) | $-1.21 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $13.85 |
| 52-week low | $1.96 | $7.29 |
| Distance from 52-week high | -56.01% | -3.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +353.51% | +25.50% |
| Average volume | 1.67M | 140.07K |
| Shares outstanding | 114.15M | 19.92M |
| Employees | 163 | 461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed CATX by 65.7 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
CATX vs INFU FAQ
Which is bigger, Perspective Therapeutics or InfuSystems?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $309.35M compared with $267.09M for InfuSystems (INFU).
Which stock has performed better over the past year, CATX or INFU?
INFU returned +36.56% over the past 12 months, compared with -29.11% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and InfuSystems in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical/Dental Instruments for InfuSystems.